29 Jun 2022

A world premiere for Metagenics!

The food supplement based on pasteurized Akkermansia muciniphila bacteria will finally be placed on the market. The product was developed by the company A-Mansia, now named The Akkermansia company™, a spin-off company from the Wageningen University and UCLouvain. The product will exclusively be distributed by Metagenics in the Benelux.


It took 17 years of research as well as a marketing authorization from the European authorities to finally see this food supplement based on Akkermansia muciniphila brought to market. Indeed, the global prevalence of obesity nearly tripled between 1975 and 2020. Excess weight affects 1.4 billion people aged 20 years or more in the world, and by 2030, it should affect 3.3 billion people. The prevalence rates for type 2 diabetes are also constantly rising.

I’m pleased to announce that we have reached an important partnership agreement with Metagenics, the Belgian market leader in food supplements, for the distribution of its first product in the Benelux region. This partnership was the obvious choice given that Metagenics is a privileged partner of doctors and pharmacists.
Michael Oredsson
CEO Akkermansia Company™
Food Supplement Akkermansia muciniphila

Availability Benelux

The food supplement will be available in pharmacy, para-pharmacy, online pharmacy or drugstores starting September 5th. Pharmacies will be able to express their interest as from June 30th!

We are very proud to be the first company to sign a partnership agreement with The Akkermansia Company™. We plan to invest in the development and management of observational studies in close collaboration with the prescribers. The products formulated with Akkermansia muciniphila pave the way for a new generation of food supplements.
Stijn Oste
VP Metagenics EMEA

What is the Akkermansia muciniphila?

As a reminder, the Akkermansia muciniphila bacterium was discovered for the first time in 2004. It was isolated from the human intestinal microbiota and characterized at the laboratory of Professor Willem M. de Vos (Wageningen University, Netherlands), co-founder of The Akkermansia Company™. Soon after, the team of Professor Patrice D. Cani (UCLouvain, Bruxelles, Belgium), the other co-founder of the company, discovered the beneficial effects of this bacterium.

Akkermansia muciniphila bacteria restores intestinal barrier function, which decreases inflammation and, over time, helps to control fat storage, glucose metabolism and energy expenditure. Better yet, the pasteurization process increases the effectiveness of Akkermansia. In pasteurized form, it is stable, it has a long storage life and is easy to administer to people.

This collaboration has resulted in dozens of scientific publications and a clinical study on human subjects. Results showed that Akkermansia muciniphila has the ability to limit the risk of deterioration of the health (prediabetes, cardiovascular risks). Researchers have observed a decrease of inflammatory markers in liver, insulin resistance or hypercholesterolemia

This distribution agreement is the first of many. It will make it possible to generate income which will be reinvested in R&D and in the creation of jobs in Wallonia. To mark this milestone, we decided to change the name of our company: A-Mansia Biotech has now become The Akkermansia Company™
Michael Oredsson
CEO Akkermansia Company™

A world premiere for Metagenics Europe!

We are the preferred and exclusive partner of The Akkermansia company™